Blockade of alternative complement pathway in dense deposit disease

Area of Science:

• Nephrology
• Immunology
• Genetics

Background:

• Dense deposit disease (DDD) is a rare kidney disorder characterized by complement system dysregulation.
• This case involves a 17-year-old with DDD, complement activation, circulating C3 Nef, and a Factor H mutation, presenting with nephrotic syndrome and hypertension.
• Previous treatments including steroids, plasma exchange, and rituximab were ineffective.

Purpose of the Study:

• To evaluate the efficacy of eculizumab, a terminal complement inhibitor, in a patient with dense deposit disease refractory to other therapies.
• To assess the impact of blocking the C5 component of the complement cascade on proteinuria and hypertension in DDD.

Main Methods:

• The patient received eculizumab, a monoclonal antibody targeting C5.
• Dosing was adjusted to maintain CH50 levels below 10% to ensure maximal terminal complement inhibition.
• Clinical outcomes, including proteinuria and blood pressure, were monitored over a 3-month period.

Main Results:

• Despite successful normalization of the soluble C5b9 complex (a marker of terminal complement activation), eculizumab treatment did not improve proteinuria or hypertension.
• The patient's clinical condition remained unchanged after 3 months of targeted C5 inhibition.

Conclusions:

• Terminal complement pathway inhibition with eculizumab was ineffective in treating this patient with dense deposit disease.
• These findings suggest that complement overactivation in DDD may involve pathways beyond C5, or that other factors contribute to disease pathogenesis.
• Further research is needed to understand the complex role of the complement system in DDD and to identify alternative therapeutic targets.